🇨🇳🇺🇸 Chinese ADRs Stock Screener — NYSE & NASDAQ China

The institutional-grade screener for US-listed Chinese stocks (ADRs). Built for long-short equity funds, macro PMs, and prop desks who want China exposure but can't (or won't) trade onshore A-shares. Pulls live USD prices, market cap, P/E, P/B, dividend yield, VIE structure flags, and HKEX dual-listing tickers for every Chinese ADR that matters — from Alibaba (BABA), Pinduoduo (PDD), and JD.com on NYSE and NASDAQ down to mid-cap names like Kanzhun (BZ), Vipshop (VIPS), and GDS Holdings.

---

Why NexGenData Chinese ADRs Stock Screener Beats Bloomberg Terminal, Capital IQ, and Refinitiv Eikon

Feature	NexGenData Chinese ADRs Screener	Bloomberg Terminal	Capital IQ (S&P)	Refinitiv Eikon / LSEG Workspace	Yahoo Finance / FinViz
Cost	$0.05/record pay-per-result	$$$$ ($24,000+/yr seat)	$$$$ ($12,000-$30,000/yr seat)	$$$$ ($22,000+/yr seat)	Free (rate-limited, ADR-tagging not surfaced)
Coverage	Every U.S.-listed Chinese ADR — BABA, JD, PDD, BIDU, NTES, TME, LI, NIO, XPEV — USD price, market cap, P/E, EPS, sector, HFCAA-delisting flag, dual-primary-HK flag, VIE structure flag	Global incl. ADRs but $24K/yr	Global incl. ADRs, S&P fundamentals	Global incl. ADRs	Global incl. ADRs but no VIE / HFCAA / dual-primary flags
Update frequency	Daily close + intraday refresh	Real-time tick	Daily	Real-time tick	Delayed 15min
API access	Apify Actor — JSON/CSV/Excel/Parquet	Bloomberg API / BBG Anywhere	Capital IQ API	Refinitiv RDP API	Yahoo unofficial scrape (breaks often)
Auth required	Apify token (free tier available)	Bloomberg seat license	Capital IQ enterprise contract	Refinitiv enterprise contract	None, but throttled

Why Chinese ADRs (And Why A Dedicated Screener)

Chinese American Depositary Receipts are the cleanest way for US-based institutional capital to get long or short exposure to Chinese growth equity. They settle in USD, trade on US hours, clear through US prime brokers, and avoid every operational headache of QFII, Stock Connect, or H-share access. For a US-based hedge fund running a 1940 Act-compliant book, ADRs are often the only way to express a China view.

But the universe is fragmented across two exchanges (NYSE, NASDAQ), spans roughly 250 tickers (of which 75-100 are institutionally relevant), and carries idiosyncratic risk vectors that don't apply to other US-listed equities:

• VIE (Variable Interest Entity) structure — most Chinese tech ADRs (BABA, JD, PDD, BIDU) don't legally own the China operating company; they own a Cayman holdco with contractual claims on profit. The SEC has flagged this. The actor surfaces a vie_structure: true/false boolean for every name so you can build VIE-vs-non-VIE basket trades.
• HKEX dual listing — post-2021 delisting risk, many large Chinese ADRs (BABA/9988, JD/9618, BIDU/9888, NTES/9999, BILI/9626, LI/2015, NIO/9866, XPEV/9868) dual-listed in Hong Kong as a regulatory hedge. The screener emits the HKEX dual ticker so you can pair-trade or build conversion-arb books.
• PRC onshore listings — a handful of Chinese ADRs (LFC, BeiGene, JinkoSolar, Daqo) also have A-share listings on Shanghai (SSE) or Shenzhen (SZSE). The actor flags prc_listing_status with the A-share ticker so you can run premium/discount analytics.
• OTC / delisted names — DiDi Global (DIDI), Luckin Coffee (LKNCY), China Mobile (CHL), and China Telecom (CHA) are no longer NYSE-listed but still trade OTC. Some funds continue to hold and trade them; we include them with listing_status: "OTC" so they don't drop out of your universe.

---

What You Get

Run the actor and you receive a clean JSON dataset, one record per Chinese ADR, with every field you'd expect plus the China-specific extras:

{
  "ticker": "BABA",
  "company_name": "Alibaba Group Holding Limited",
  "listing_exchange": "NYSE",
  "listing_status": "Listed",
  "price_usd": 84.31,
  "currency": "USD",
  "previous_close": 83.55,
  "open": 83.92,
  "day_high": 85.10,
  "day_low": 83.40,
  "change": 0.76,
  "change_percent": 0.91,
  "volume": 19842500,
  "avg_volume_3m": 17500000,
  "market_cap_usd_billion": 204.5,
  "pe_ratio": 16.2,
  "forward_pe": 9.8,
  "price_to_book": 1.6,
  "dividend_yield_percent": 1.18,
  "fifty_two_week_high": 117.82,
  "fifty_two_week_low": 66.63,
  "sector": "Consumer Discretionary",
  "vie_structure": true,
  "hkex_dual_listing": true,
  "hkex_dual_ticker": "9988",
  "prc_listing_status": null,
  "yahoo_quote_url": "https://finance.yahoo.com/quote/BABA",
  "stockanalysis_url": "https://stockanalysis.com/stocks/baba/",
  "data_source": "yahoo_finance"
}

That's everything you need to:

• Build a Chinese ADR universe screen in Python/R/Excel
• Compute basket weightings (cap-weighted, equal-weighted, ADV-weighted)
• Run premium/discount vs HKEX dual listings (combine with our Hang Seng screener)
• Drop into a long-short relative-value book vs SPY/QQQ benchmarks
• Feed a sector-rotation overlay (Tech vs Consumer Discretionary vs Education)

---

Input Filters

Input	Type	Description
limit	integer	Max stocks to return (0 = all ~85). Use 10 for testing.
listing_exchange	enum	all / NYSE / NASDAQ / OTC
min_market_cap_usd_billion	integer	Filter out micro caps. Use 10 for mega-cap-only.
sector	enum	Tech, Consumer Discretionary, Comm Services, Education, Healthcare, etc.
vie_only	boolean	Return only companies that use VIE structure
include_hkex_dual	boolean	Return only Chinese ADRs that also list in Hong Kong

---

Use Cases For Institutional Capital

Long-short equity funds

Run a long Chinese ADR book vs a short US tech basket (e.g., long BABA/PDD/JD vs short AMZN/SHOP/EBAY). Use this actor as the daily universe refresh; combine with our Finviz screener to build the US short side.

Macro / global thematic funds

Track aggregate Chinese ADR market cap, sector rotation, and 52-week ranges. Useful for China beta sizing without trading the underlying RMB-denominated A-shares.

Pair-trade / arbitrage desks

For the 25+ Chinese ADRs that are HKEX dual-listed (BABA/9988, JD/9618, NIO/9866 etc.), build the daily ADR-vs-H-share spread. Combine with our HKEX screener to track both sides intraday.

Risk / compliance teams

The vie_structure boolean is a critical regulatory flag. SEC's Holding Foreign Companies Accountable Act (HFCAA) and PCAOB inspection regime put VIE-structured names at delisting risk. Pull a daily VIE-only list to feed into your risk committee dashboards.

Quant signal research

Use the unified USD pricing + listing exchange + sector tags to backtest momentum, value, and quality factors across the Chinese ADR universe. Combine with HKEX data via our Hang Seng screener to construct cross-listing premium/discount factors.

---

Pricing — Pay Per Stock

Event	Cost
Actor start	$0.01
Per Chinese ADR returned	$0.25

A 10-stock smoke test costs $2.51 total. A full ~85-stock universe pull costs ~$21.26. Cheaper than a single Bloomberg ADR-FX-Y monthly seat by three orders of magnitude. No subscription, no minimum commitment — pay only when you run.

---

Data Sources & Reliability

1. Yahoo Finance batch quote endpoint (primary). One HTTP call per batch of 40 tickers returns 30+ fields per name.
2. stockanalysis.com per-symbol pages (fallback). If Yahoo rate-limits (HTTP 429) the actor falls back to per-symbol HTML scraping so you still get prices and market caps.
3. Static curated metadata (always available). Listing exchange, VIE flag, HKEX dual ticker, sector, and PRC A-share linkage are hardcoded from authoritative sources (SEC EDGAR, NYSE/NASDAQ listings APIs, HKEX disclosure data) and won't break if a source goes down.

The universe is curated to ~85 institutionally-relevant Chinese ADRs. We deliberately exclude shell-company / reverse-merger names that crowd the long tail but rarely trade above $10M ADV.

---

Cross-Reference Our Other China & Equity Actors

Chinese ADRs are one slice of the full China-and-broader equity stack. Pair this actor with:

• 🇨🇳 Eastmoney China Stock Screener — onshore A-share screener (SSE + SZSE). Use when you have QFII or Stock Connect access and want the raw mainland universe instead of the ADR proxy.
• 🇭🇰 HKEX Hang Seng Stock Screener — Hong Kong-listed equities, including the HKEX dual listings of every Chinese ADR. Essential for premium/discount and pair-trade desks.
• 🇺🇸 Finviz Stock Screener — US equity screener for the rest of your book. Build the US short side of a China long-short, or run sector-relative valuation against the S&P 500.

All three integrate identically: same JSON output, same ?build=latest pinning, same Apify dataset format.

---

How To Run

Apify Console — paste your filter inputs, hit Run, download the dataset as JSON or CSV.

Apify API (Python):

import apify_client
client = apify_client.ApifyClient("YOUR_TOKEN")
run = client.actor("nexgendata/chinese-adrs-stock-screener").call(run_input={
    "limit": 50,
    "listing_exchange": "all",
    "min_market_cap_usd_billion": 5,
    "vie_only": False,
})
for item in client.dataset(run["defaultDatasetId"]).iterate_items():
    print(item["ticker"], item["price_usd"], item["market_cap_usd_billion"])

Schedule it — the actor pairs naturally with an Apify scheduled task. Daily 16:30 ET (after US close) gives you a fresh universe snapshot every market day.

---

FAQ

How fresh is the data? Live. Yahoo Finance quotes update every 15 seconds (delayed) for most ADRs; you get the latest snapshot each run.

Does it cover DIDI? Yes — DIDI Global is included with listing_status: "OTC" since it delisted from NYSE in 2022 but still trades on OTC markets.

What about new IPOs (e.g., Zeekr / ZK)? Yes — Zeekr (ZK), MNSO (Miniso), BZ (Kanzhun), BEKE are all included.

Why are some sectors named differently than Yahoo's? We use GICS-aligned sector names harmonized across our China actor fleet. So Communication Services covers BIDU, NTES, BILI, WB, TME consistently across this actor and our Hang Seng / Eastmoney screeners.

Can I get OHLCV history? Not yet — this actor returns a single live snapshot. For history, pair with our other US equity actors or pull from Yahoo via the yahoo_quote_url field we emit.

---

Built By NexGenData

We build data infrastructure for global equity desks. 130+ actors live on Apify covering US, China, Hong Kong, Japan, Korea, and emerging markets. If you're building a fund-grade data pipeline and want our actors bundled, white-labeled, or extended with custom fields — reach out.

Get free Apify credits & save 30% on platform fees: https://apify.com/nexgendata?fpr=2ayu9b

---

Explore the NexGenData Equity Data Suite

This actor is part of NexGenData's global equity data fleet. Whether you cover a single region or a multi-asset macro book, we have a screener for every major market:

Regional sisters

• 🔗 Eastmoney China A-Share Screener — Shanghai + Shenzhen + STAR + ChiNext full A-share universe — the broadest Chinese equity screener.
• 🔗 HKEX Hang Seng Stock Screener — Hang Seng + HSCEI live quotes, market cap (HKD), P/E, dividend yield, sector — Tencent, HSBC, AIA universe.
• 🔗 STAR Market Screener (China) — Shanghai STAR Market 50 fundamentals, market cap (RMB), P/E, P/B, sector — China's NASDAQ-equivalent hard-tech board.

Cross-region peers

• 🔗 Finviz Stock Screener (US) — US equities (NYSE / NASDAQ / AMEX) with 70+ filters — market cap, P/E, sector, technicals, insider activity.
• 🔗 ChiNext Screener (China) — Shenzhen ChiNext fundamentals, market cap (RMB), P/E, P/B, sector — CATL, Mindray, East Money, Sungrow universe.

Multi-asset / specialty

• 🔗 Finance MCP Server — Unified Model Context Protocol server exposing the full NexGenData equity fleet to Claude, Cursor & MCP-aware LLMs.

Browse the full NexGenData catalog

→ See all 220+ NexGenData actors at apify.com/nexgendata — equity screeners across 25+ markets, lead generation, SEC filings, B2B intelligence, MCP servers, and more.

---

Why NexGenData vs. paid alternatives

Tool	Annual cost	API access	Coverage
Bloomberg Terminal	~$24,000/seat	Limited	Global
FactSet	~$15,000/seat	Paid add-on	Global
Refinitiv Eikon	~$22,000/seat	Paid add-on	Global
S&P Capital IQ	~$20,000/seat	Paid add-on	Global
NexGenData China ADRs (US-listed) Screener	Pay-per-result	Native	China ADRs (US-listed)

Run this actor once per day for a typical institutional-scale workflow (~200 records/day) and your annual cost is approximately $1,800–2,000 — a 90-95% discount vs. the major paid alternatives, with no seat licensing, no minimum commitment, and full programmatic access.

Related NexGenData Actors — China Stock Intelligence

Use case	Actor
STAR Market Shanghai tech (科创板)	STAR Market China Stock Screener
ChiNext Shenzhen growth (创业板)	ChiNext China Stock Screener
BSE Beijing innovation tier	BSE Beijing Stock Screener
China A-share aggregate	Eastmoney China Stock Screener
Hong Kong Hang Seng	HKEX Hang Seng Stock Screener
KOSPI Korea fundamentals	KOSPI Stock Screener
Singapore SGX (STI + S-REITs)	SGX Singapore Stock Screener